Yttrium 90 radioembolization: The horizon is changing for patients with intermediate and advanced hepatocellular carcinoma

Hepatology

Volumn 57, Issue 5, 2013, Pages 1694-1696

  Bolondi, Luigi ^a   Piscaglia, Fabio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SORAFENIB; YTTRIUM 90;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CLINICAL PROTOCOL; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSARTERIAL RADIOEMBOLIZATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; SEVERITY OF ILLNESS INDEX; YTTRIUM RADIOISOTOPES;

EID: 84876702614     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26154     Document Type: Article

References (11)

1. European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
3. Bolondi L, Burroughs AK, Dufour JF, Galle P, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) HCC. Proposal for a subclassification to facilitate treatment decisions. Sem Liver Dis 2012 (In press).
4. Raoul JL, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, Lencioni R. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2010; 37: 212-220.
5. Terzi E, Golfieri R, Piscaglia F, Galassi M, Dazzi A, Leoni S, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". J Hepatol 2012; 57: 1258-1267.
6. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29: 339-364.
7. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
8. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
9. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. HEPATOLOGY 2011; 54: 868-878.
10. Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C, et al. Yttrium(90) radioembolization for intermediate-advanced hepatocarcinoma: a phase II study. HEPATOLOGY 2013; 57: 1826-1837.
11. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.